Loading
institutionsInstitution
Wellcome
One of the world's largest charitable science funders and a founding partner of the Francis Crick Institute and the Wellcome Sanger Institute, home of the COSMIC cancer mutation database.
Also called: Wellcome Trust
Overview
Established in 1936 from the estate of Henry Wellcome, Wellcome is a politically and financially independent foundation that funds discovery science, and its portfolio underpins cancer research even though it is not a cancer-specific funder. It co-founded the Francis Crick Institute with Cancer Research UK and the Medical Research Council, and it established the Wellcome Sanger Institute, whose Cancer Genome Project produced COSMIC and much of the mutational-signature literature. Wellcome funds investigator awards, clinical research career development and the Human Cell Atlas, and it drove open-access publishing policy through Plan S and Europe PMC.
Location
London, GB
Type
consortium
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#433 · 12 points (0 Newsweek + 0 NCI + 12 from 6 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-17.
Matched to Wellcome Trust, including child institutions. 349 works · 4,940 citations · 88% open access · 2% clinical trials · 3% reviews.
Oncology works per year
902022
822023
602024
642025
532026
Most works
- Danail Stoyanov18 works
- Laurence Lovat17 works
- David J. Adams17 works
- Omer F. Ahmad16 works
- Rawen Kader15 works
- Douglas P. Dyer9 works
- Peter Mountney9 works
- Ann M. Moormann9 works
- Benjamin D. Simons8 works
- Ingrid Ferreira8 works
Most cited
- Wellcome Sanger Institute (COSMIC, mutational signatures)
- Francis Crick Institute founding partner
- Discovery research awards
- Open access and Europe PMC
John-Arne Røttingen
Chief Executive Officer
Global healthResearch fundingHealth policy
Norwegian physician and global health leader who has been Chief Executive of Wellcome, one of the world's largest biomedical research funders, since 2024.
Paul Nurse
Director, Francis Crick Institute; Nobel laureate
Cell cycleCyclin-dependent kinasesInstitute leadership
Nobel laureate who discovered how cyclin-dependent kinases control cell division, and founding director of the Crick.
Charles Swanton
Deputy Clinical Director, Francis Crick Institute; Chief Clinician, Cancer Research UK
Tumour evolutionLung cancerCirculating tumour DNA
Leads TRACERx, the study that follows lung cancers as they evolve, and showed how air pollution can trigger lung cancer without new mutations.
Similar pages
- IdeaPool every multi-sample tumour genome into one open evolution atlas
Shares The Francis Crick Institute, Data silos, Cancer Research UK, Whole-exome & whole-genome sequencing.
- IdeaA national rapid research autopsy network for end-stage cancer
Shares The Francis Crick Institute, Single-cell & spatial profiling, Cancer Research UK, Whole-exome & whole-genome sequencing.
- IdeaBank three spatially separate tumour blocks from every resection
Shares The Francis Crick Institute, Data silos, Cancer Research UK, Whole-exome & whole-genome sequencing.
- IdeaA global rapid tissue donation network for metastatic disease
Shares Charles Swanton, Single-cell & spatial profiling, Data silos, Whole-exome & whole-genome sequencing.
- InstitutionCancer Grand Challenges
Shares Charles Swanton, The Francis Crick Institute, Mutational signature, Cancer Research UK.
- Key paperGerlinger: a single biopsy misses most of the mutations in a kidney tumour
Shares Charles Swanton, The Francis Crick Institute, Cancer Research UK, Whole-exome & whole-genome sequencing.
- TrialTRACERx
- Key paperTRACERx 421: the full-cohort picture of how lung cancer evolves and which subclones drive relapse
Shares Charles Swanton, The Francis Crick Institute, Cancer Research UK, Whole-exome & whole-genome sequencing.